Video
Dr. Pinato on Study of Sorafenib in Pretreated Patients With HCC
Author(s):
David James Pinato, MD, MRCP, PhD, faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of sorafenib (Nexavar) in pretreated patients with hepatocellular carcinoma (HCC).
David James Pinato, MD, MRCP, PhD, faculty of Medicine, Department of Surgery and Cancer, NIHR Academic Clinical Lecturer, Imperial College London, discusses a study of sorafenib (Nexavar) in pretreated patients with hepatocellular carcinoma (HCC).
This was an observational study conducted to establish whether prior treatment to sorafenib was a determinant of survival in patients with HCC.
It did not matter whether the patient was in an advanced stage of the disease or intermediate, says Pinato—if they had received treatment prior to starting sorafenib, their survival was better.
According to Pinato, this study shows that the sequencing of treatment in this patient population can have an effect on survival.
